Type 2 diabetes

PBS subsidies for oral triple therapy with DPP-4 and SGLT2 inhibitors

Triple oral therapy with a DPP-4 inhibitor and SGLPT2 inhibitor in addition to metformin will be subsidised on the PBS from 1 April. Fixed dose combinations of SGLP2 inhibitors and gliptins are among a raft of diabetes treatments to be listed on the PBS, in addition to a longer-acting insulin glargine product, Toujeo. A combination ...

Already a member?

Login to keep reading.

© 2021 the limbic